In 2021, Philadelphia continued to prove why it’s an up-and-coming life sciences and biotech cluster. Current reports state the city received $1.23 billion in National Institute of Health (NIH) funding in 2021 — and that number is expected to be bigger once finalized, said Lauren Gilchrist, Managing Director of Research at Longfellow Real Estate Partners.
The Center for Breakthrough Medicines (CBM) announced today that it has received $350 million in equity financing from SK Inc. (KRX: 034730) (SK). CBM is partnering with SK to create the world’s largest end-to-end cell and gene therapy contract development and manufacturing organization (CDMO).
Castle Creek Biosciences, Inc., a late-clinical stage cell and gene therapy company focused on developing and preparing to commercialize disease-modifying and potentially curative therapies for rare genetic diseases, today announced it has acquired Novavita Thera, Inc., a preclinical gene therapy company focused on rare liver and metabolic diseases. The acquisition expands Castle Creek’s technology platform by adding in vivo capabilities to its existing ex vivo approach, and broadens Castle Creek’s development pipeline beyond skin and connective tissue disorders to rare liver diseases.
COVAXIN™ (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety Participants receiving a booster dose six months after second dose of COVAXIN™ saw significant increase (>10-fold across Alpha, [….]
Moderna Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Carisma Therapeutics Inc., a biopharmaceutical pioneer in engineered macrophage-based therapeutics, today announced that the two companies have entered into a strategic collaboration agreement to discover, develop and commercialize in vivo engineered chimeric antigen receptor monocyte (CAR-M) therapeutics for the treatment of cancer.
Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology and rare genetic diseases, today provides a comprehensive update on the Company’s growth opportunities and mid-stage development portfolio.
Dynacure, a clinical stage biotechnology company focusing on Myotubular and Centronuclear Myopathies (CNM), a group of rare, debilitating, and life-threatening genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its lead product candidate, DYN101. The Fast Track process is designed to facilitate the development and expedite the review of drugs to treat serious conditions and address significant unmet medical need.
AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a US and China-based biotechnology company focused on early cancer screening and detection, announced today that on December 30, 2021, the Company’s Class III medical device for lung cancer auxiliary diagnosis has completed and passed stringent and rigorous registration tests at the testing laboratory designated by the National Medical Products Administration (NMPA), China’s regulatory agent for medical products. China’s extensive Class III medical device registration tests included medical device performance tests related to accuracy, precision, stability, linearity, accuracy and repeatability in sample addition, cross-contamination, electromagnetic compatibility (EMC), and reliability and performance under various environmental conditions. Completion of the NMPA registration tests is a significant milestone toward obtaining a Class III medical device registration certificate. Following completion of the registration test, the remaining major step prior to final approval of a registration certificate will be clinical trials which will begin in the first quarter of 2022 with two qualified clinical trial medical institutions.
Executive Women In Bio (EWIB), a Women In Bio (WIB) initiative, celebrates a milestone year in 2021 with the 100th Boardroom Ready Alumnae appointment to a corporate board in the life science industry. This year alone, more than 40 appointments took place, totaling 112 placements since the program’s inception. Boardroom Ready is an award-winning executive development platform designed to fuel women’s participation on corporate boards.
Women In Bio (WIB), a national organization of professionals committed to promoting the careers, leadership and entrepreneurship of all women in the life sciences, has elected Dr. Azurii Collier of the Greater Chicago area as the 2022 National President-Elect. Collier currently serves as the WIB-National Sponsorship Committee Chair and previously served as WIB-National Sponsorship Committee Co-Chair and as an active member of Women In Bio for six years.
